Brand Name(s): Cefzil

CAS nš: 92665-29-7

(sef proe' zil)

About Cefprozil

This new site is dedicated exclusively to Cefprozil.

It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumer or pharma industry professional, you can now find out everything you need to know about cefprozil, as well as take part in our open discussion forum by sharing your own knowledge and experiences with people who are using this medication.

This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total cefprozil experience! 

Why is this medication prescribed?

Cefprozil is effective against susceptible bacteria causing infections of the middle ear, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia, and skin and soft tissue infections.

This medicine is a semi-synthetic oral antibiotic of the cephalosporin family. Cefprozil is active against a very wide spectrum of bacteria, including staphylococcus, aureus, streptococcus pyogenes (the cause of strep throat), hemophilus influenzae, moraxella catarrhalis, E. coli, klebsiella, proteus mirabilis, salmonella, shigella, clostridium perfringens and neisseria gonorrhoeae.

See more Product Info

Latest News

Aurobindo Pharma gets US FDA nod for Cefprozil

Drug maker Aurobindo Pharma Ltd. said on Friday it received the U.S. Food and Drug Administration...

[more]

FLAVORx Reports Show December Brings Flavor to Commonly Prescribed Antibiotics

Recent pharmacy reports showed that, in December, the most commonly flavored medications were...

[more]

Ranbaxy Labs gets USFDA approval for Cefprozil

Ranbaxy Laboratories received an approval from the US Food and Drug Administration to manufacture...

[more]

Ranbaxy Q2 global sales at Rs 14,464 mn, 7% growth

The Board of Directors of Ranbaxy Laboratories Limited (RLL) at their meeting held today took on...

[more]

Ranbaxy Receives Approval to Market Cefprozil Suspension

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited...

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.